Abstract
Background: Management of T2DM commonly requires a combination of several antidiabetic drugs to achieve optimal glycemic control. However, limited number of fixed dose combination (FDCs) are available. Teneligliptin is one of the most commonly prescribed dipeptidyl peptidase 4 inhibitor (DPP4i) in India, but not available in FDC with any Sodium-Glucose co-transporter 2 inhibitor (SGLT2i). Remogliflozin Etabonate (RE) is novel SGLT2i recently approved in India. The FDC of Teneligliptin with RE has been evaluated in this pivotal phase III study.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
